Glycosylation and liver cancer

Advances in Cancer Research

Volumn 126, Issue , 2015, Pages 257-279

  Mehta, Anand ^a   Herrera, Harmin ^a   Block, Timothy ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Fucosylation; Glycomics; Glycoproteomics; Glycosylation; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Liver cancer; Nash

Indexed keywords

ALPHA FETOPROTEIN; ARYLDIALKYLPHOSPHATASE 1; AUTOANTIBODY; CERULOPLASMIN; FETUIN A; GLYCAN; HAPTOGLOBIN; HEMOPEXIN; OSTEOPONTIN; PEROXIREDOXIN 3; GLYCOPROTEIN; TUMOR PROTEIN;

ARTICLE; CANCER PATIENT; CANCER RISK; CANCER TISSUE; CELL GROWTH; FUCOSYLATION; GLYCOBIOLOGY; GLYCOSYLATION; HEPATITIS; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEOMICS; SIALYLATION; SURVIVAL RATE; VIRUS INFECTION; ANIMAL; LIVER TUMOR; METABOLISM; PATHOLOGY;

ANIMALS; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; LIVER NEOPLASMS; NEOPLASM PROTEINS;

EID: 84923518201     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/bs.acr.2014.11.005     Document Type: Chapter

References (172)

1. Abu El Makarem M.A., Abdel-Aleem A., Ali A., Saber R., Shatat M., Rahem D.A., et al. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Annals of Hepatology 2011, 10:296-305.
2. Ahn Y.H., Shin P.M., Ji E.S., Kim H., Yoo J.S. A lectin-coupled, multiple reaction monitoring based quantitative analysis of human plasma glycoproteins by mass spectrometry. Analytical and Bioanalytical Chemistry 2012, 402:2101-2112.
3. Ahn Y.H., Shin P.M., Oh N.R., Park G.W., Kim H., Yoo J.S. A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma. Journal of Proteomics 2012, 75(17):5507-5515.
4. Ahn J.M., Sung H.J., Yoon Y.H., Kim B.G., Yang W.S., Lee C., et al. Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer. Molecular & Cellular Proteomics 2014, 13:30-48.
5. Ai J., Tan Y., Ying W., Hong Y., Liu S., Wu M., et al. Proteome analysis of hepatocellular carcinoma by laser capture microdissection. Proteomics 2006, 6:538-546.
6. Aoyagi Y. Molecular discrimination between alpha-fetoprotein from patients with hepatocellular-carcinoma and nonneoplastic liver-diseases by their carbohydrate structures (review). International Journal of Oncology 1994, 4:369-383.
7. Aoyagi Y., Isokawa O., Suda T., Watanabe M., Suzuki Y., Asakura H. The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. Cancer 1998, 83:2076-2082.
8. Aoyagi Y., Mita Y., Suda T., Kawai K., Kuroiwa T., Igarashi M., et al. The fucosylation index of serum alpha-fetoprotein as useful prognostic factor in patients with hepatocellular carcinoma in special reference to chronological changes. Hepatology Research 2002, 23:287.
9. Aoyagi Y., Suzuki Y., Igarashi K., Saitoh A., Oguro M., Yokota T., et al. Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: Presence of fucosylated and non-fucosylated triantennary glycans. British Journal of Cancer 1993, 67:486-492.
10. Aoyagi Y., Suzuki Y., Igarashi K., Yokota T., Mori S., Suda T., et al. Highly enhanced fucosylation of alpha-fetoprotein in patients with germ cell tumor. Cancer 1993, 72:615-618.
11. Aoyagi Y., Suzuki Y., Isemura M., Nomoto M., Sekine C., Igarashi K., et al. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 1988, 61:769-774.
12. Asazawa H., Kamada Y., Takeda Y., Takamatsu S., Shinzaki S., Kim Y., et al. Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development. Clinical Chemistry and Laboratory Medicine 2015, 53(1):95-102.
13. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988, 61:1942-1956.
14. Benvegnu L., Fattovich G., Noventa F., Tremolada F., Chemello L., Cecchetto A., et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994, 74:2442-2448.
15. Block T.M., Comunale M.A., Lowman M., Steel L.F., Romano P.R., Fimmel C., et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:779-784.
16. Block T.M., Mehta A.S., Fimmel C.J., Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003, 22:5093-5107.
17. Bosch F.X., Ribes J., Borras J. Epidemiology of primary liver cancer. Seminars in Liver Disease 1999, 19:271-285.
18. Brechot C. Hepatitis B virus (HBV) and hepatocellular carcinoma. HBV DNA status and its implications. Journal of Hepatology 1987, 4:269-279.
19. Brechot C. Hepatitis B and C viruses and primary liver cancer. Baillière's Clinical Gastroenterology 1996, 10:335-373.
20. Buamah P.K., Cornell C., Cassells-Smith A.J., Harris A.L. Fucosylation of alpha-fetoprotein in hepatocellular carcinomas. Lancet 1986, 1:922-923.
21. Callewaert N., Schollen E., Vanhecke A., Jaeken J., Matthijs G., Contreras R. Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I. Glycobiology 2003, 13:367-375.
22. Cao Y., Chang H., Cheng R.-C., Fan X.-N. Alteration of adhesion molecule expression and cellular polarity in hepatocellular carcinoma. Histopathology 2007, 51:528-538.
23. Chahed K., Kabbage M., Hamrita B., Guillier C.L., Trimeche M., Remadi S., et al. Detection of protein alterations in male breast cancer using two dimensional gel electrophoresis and mass spectrometry: The involvement of several pathways in tumorigenesis. Clinica Chimica Acta; International Journal of Clinical Chemistry 2008, 388:106-114.
24. Chandler K.B., Pompach P., Goldman R., Edwards N. Exploring site-specific N-glycosylation microheterogeneity of haptoglobin using glycopeptide CID tandem mass spectra and glycan database search. Journal of Proteome Research 2013, 12:3652-3666.
25. Chen C.Y., Jan Y.H., Juan Y.H., Yang C.J., Huang M.S., Yu C.J., et al. Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:630-635.
26. Chen R., Wang F., Tan Y., Sun Z., Song C., Ye M., et al. Development of a combined chemical and enzymatic approach for the mass spectrometric identification and quantification of aberrant N-glycosylation. Journal of Proteomics 2012, 75:1666-1674.
27. Chen R.X., Xia Y.H., Cui J.F., Xue T.C., Ye S.L. Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection. Journal of Gastroenterology and Hepatology 2010, 25:1435-1442.
28. Chen R.X., Xia Y.H., Xue T.C., Ye S.L. Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression. Molecular Biology Reports 2011, 38:3671-3677.
29. Chen X.L., Zhou L., Yang J., Shen F.K., Zhao S.P., Wang Y.L. Hepatocellular carcinoma-associated protein markers investigated by MALDI-TOF MS. Molecular Medicine Reports 2010, 3:589-596.
30. Chignard N., Beretta L. Proteomics for hepatocellular carcinoma marker discovery. Gastroenterology 2004, 127:S120-S125.
31. Comunale M.A., Lowman M., Long R.E., Krakover J., Philip R., Seeholzer S., et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. Journal of Proteome Research 2006, 5:308-315.
32. Comunale M.A., Rodemich-Betesh L., Hafner J., Wang M., Norton P., Di Bisceglie A.M., et al. Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: Implications for a biomarker of hepatocellular carcinoma. PLoS One 2010, 5:e12419.
33. Comunale M.A., Wang M., Hafner J., Krakover J., Rodemich L., Kopenhaver B., et al. Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. Journal of Proteome Research 2009, 8:595-602.
34. Comunale M.A., Wang M., Rodemich-Betesh L., Hafner J., Lamontagne A., Klein A., et al. Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2011, 20:1222-1229.
35. Debruyne E.N., Vanderschaeghe D., Van Vlierberghe H., Vanhecke A., Callewaert N., Delanghe J.R. Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clinical Chemistry 2010, 56:823-831.
36. Dennis J.W., Granovsky M., Warren C.E. Glycoprotein glycosylation and cancer progression. Biochimica et Biophysica Acta 1999, 1473:21-34.
37. Dennis J.W., Laferte S., Waghorne C., Breitman M.L., Kerbel R.S. Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 1987, 236:582-585.
38. Deuffic S., Poynard T., Buffat L., Valleron A.J. Trends in primary liver cancer. Lancet 1998, 351:214-215.
39. Di Bisceglie A.M., Carithers R.L., Gores G.J. Hepatocellular carcinoma. Hepatology 1998, 28:1161-1165.
40. Ding S.J., Li Y., Shao X.X., Zhou H., Zeng R., Tang Z.Y., et al. Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics 2004, 4:982-994.
41. Drake R.R., Schwegler E.E., Malik G., Diaz J., Block T., Mehta A., et al. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Molecular & Cellular Proteomics 2006, 5:1957-1967.
42. El-Serag H.B., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. The New England Journal of Medicine 1999, 340:745-750.
43. Feng J.T., Liu Y.K., Song H.Y., Dai Z., Qin L.X., Almofti M.R., et al. Heat-shock protein 27: A potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 2005, 5:4581-4588.
44. Goldman R., Ressom H.W., Varghese R.S., Goldman L., Bascug G., Loffredo C.A., et al. Detection of hepatocellular carcinoma using glycomic analysis. Clinical Cancer Research 2009, 15:1808-1813.
45. Goodarzi M.T., Turner G.A. Decreased branching, increased fucosylation and changed sialylation of alpha-1-proteinase inhibitor in breast and ovarian cancer. Clinica Chimica Acta; International Journal of Clinical Chemistry 1995, 236:161-171.
46. Gu Y., Chen W., Zhao Y., Chen L., Peng T. Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases. Annals of Clinical Biochemistry 2009, 46:38-43.
47. Guo H.B., Johnson H., Randolph M., Nagy T., Blalock R., Pierce M. Specific posttranslational modification regulates early events in mammary carcinoma formation. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:21116-21121.
48. Guo W.X., Man X.B., Yuan H.X., Shi J., Xue J., Wu M.C., et al. Proteomic analysis on portal vein tumor thrombus-associated proteins for hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 2007, 87:2094-2097.
49. Hann H.W., Wang M., Hafner J., Long R.E., Kim S.H., Ahn M., et al. Analysis of GP73 in patients with HCC as a function of anti-cancer treatment. Cancer Biomarkers: Section A of Disease Markers 2010, 7:269-273.
50. Helenius A., Aebi M. Intracellular functions of N-linked glycans. Science 2001, 291:2364-2369.
51. Higai K., Shibukawa K., Muto S., Matsumoto K. Targeted proteo-glycomics analysis of Sialyl Lewis X antigen expressing glycoproteins secreted by human hepatoma cell line. Analytical Sciences 2003, 19:85-92.
52. Hirabayashi J. Lectin-based structural glycomics: Glycoproteomics and glycan profiling. Glycoconjugate Journal 2004, 21:35-40.
53. Hirabayashi J., Hashidate T., Kasai K. Glyco-catch method: A lectin affinity technique for glycoproteomics. Journal of Biomolecular Techniques 2002, 13:205-218.
54. Hirabayashi J., Kasai K. Glycoproteomics of C. elegans. Tanpakushitsu Kakusan Koso 2003, 48:1049-1056.
55. Hoofnagle J.H. Management of hepatitis C: Current and future perspectives. Journal of Hepatology 1999, 31:264-268.
56. Hoofnagle Jay H., Di Bisceglie Adrian M. The treatment of chronic viral hepatitis. The New England Journal of Medicine 1997, 336:347-356.
57. Hu P., Shi B., Geng F., Zhang C., Wu W., Wu X.Z. E-cadherin core fucosylation regulates nuclear beta-catenin accumulation in lung cancer cells. Glycoconjugate Journal 2008, 25:843-850.
58. Hu J.S., Wu D.W., Liang S., Miao X.Y. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Medical Oncology 2010, 27:339-345.
59. Iftikhar R., Kladney R.D., Havlioglu N., Schmitt-Graff A., Gusmirovic I., Solomon H., et al. Disease- and cell-specific expression of GP73 in human liver disease. The American Journal of Gastroenterology 2004, 99:1087-1095.
60. Ito Y., Miyauchi A., Yoshida H., Uruno T., Nakano K., Takamura Y., et al. Expression of alpha1,6-fucosyltransferase (FUT8) in papillary carcinoma of the thyroid: Its linkage to biological aggressiveness and anaplastic transformation. Cancer Letters 2003, 200:167-172.
61. Ito Y., Miyoshi E., Sakon M., Takeda T., Noda K., Tsujimoto M., et al. Elevated expression of UDP-N-acetylglucosamine: Alphamannoside beta1,6N-acetylglucosaminyltransferase is an early event in hepatocarcinogenesis. International Journal of Cancer. Journal International du Cancer 2001, 91:631-637.
62. Jiang J.C., Zhou L.F. Advances on Golgi glycoprotein 73 and its association with diseases. Zhejiang Da Xue Xue Bao. Yi Xue Ban 2012, 41:215-221.
63. Kamada Y., Akita M., Takeda Y., Yamada S., Fujii H., Sawai Y., et al. Serum fucosylated haptoglobin as a novel diagnostic biomarker for predicting hepatocyte ballooning and nonalcoholic steatohepatitis. PLoS One 2013, 8:e66328.
64. Kamiyama T., Yokoo H., Furukawa J., Kurogochi M., Togashi T., Miura N., et al. Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis. Hepatology (Baltimore, MD) 2013, 57:2314-2325.
65. Kim Y.J., Borsig L., Varki N.M., Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:9325-9330.
66. Kim J., Ki S.S., Lee S.D., Han C.J., Kim Y.C., Park S.H., et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. The American Journal of Gastroenterology 2006, 101:2051-2059.
67. Kobayashi S., Nouso K., Kinugasa H., Takeuchi Y., Tomoda T., Miyahara K., et al. Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma. Hepatology Research 2012, 42:1187-1195.
68. Kumada T., Nakano S., Takeda I., Sugiyama K., Osada T., Kiriyama S., et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997, 25:87-92.
69. Lau K.S., Partridge E.A., Grigorian A., Silvescu C.I., Reinhold V.N., Demetriou M., et al. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 2007, 129:123-134.
70. Le Naour F., Brichory F., Misek D.E., Brechot C., Hanash S.M., Beretta L. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Molecular & Cellular Proteomics 2002, 1:197-203.
71. Lehtonen S.T., Svensk A.M., Soini Y., Paakko P., Hirvikoski P., Kang S.W., et al. Peroxiredoxins, a novel protein family in lung cancer. International Journal of Cancer. Journal International du Cancer 2004, 111:514-521.
72. Li Y., Qin X., Cui J., Dai Z., Kang X., Yue H., et al. Proteome analysis of aflatoxin B1-induced hepatocarcinogenesis in tree shrew (Tupaia belangeri chinensis) and functional identification of candidate protein peroxiredoxin II. Proteomics 2008, 8:1490-1501.
73. Lin F., Li Y., Cao J., Fan S., Wen J., Zhu G., et al. Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells. Molecular Biology Reports 2011, 38:5205-5210.
74. Liu X.E., Desmyter L., Gao C.F., Laroy W., Dewaele S., Vanhooren V., et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology (Baltimore, MD) 2007, 46:1426-1435.
75. Liu Y., He J., Li C., Benitez R., Fu S., Marrero J., et al. Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. Journal of Proteome Research 2010, 9:798-805.
76. Liu X., Wan X., Li Z., Lin C., Zhan Y., Lu X. Golgi protein 73(GP73), a useful serum marker in liver diseases. Clinical Chemistry and Laboratory Medicine: CCLM/FESCC 2011, 49:1311-1316.
77. Lu Y., Liu J., Lin C., Wang H., Jiang Y., Wang J., et al. Peroxiredoxin 2: A potential biomarker for early diagnosis of hepatitis B virus related liver fibrosis identified by proteomic analysis of the plasma. BMC Gastroenterology 2010, 10:115.
78. Maitra A., Thuluvath P.J. GP73 and liver disease: A (Golgi) complex enigma. The American Journal of Gastroenterology 2004, 99:1096-1098.
79. Malaguarnera G., Giordano M., Paladina I., Berretta M., Cappellani A., Malaguarnera M. Serum markers of hepatocellular carcinoma. Digestive Diseases and Sciences 2010, 55:2744-2755.
80. Mao Y., Yang H., Xu H., Lu X., Sang X., Du S., et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010, 59:1687-1693.
81. Mao Y.L., Yang H.Y., Xu H.F., Sang X.T., Lu X., Yang Z.Y., et al. Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: A primary study. Zhonghua Yi Xue Za Zhi 2008, 88:948-951.
82. Marrero J.A., Feng Z., Wang Y., Nguyen M.H., Befeler A.S., Roberts L.R., et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009, 137:110-118.
83. Marrero J.A., Romano P.R., Nikolaeva O., Steel L., Mehta A., Fimmel C.J., et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. Journal of Hepatology 2005, 43:1007-1012.
84. Matsumoto K., Maeda Y., Kato S., Yuki H. Alteration of asparagine-linked glycosylation in serum transferrin of patients with hepatocellular carcinoma. Clinica Chimica Acta; International Journal of Clinical Chemistry 1994, 224:1-8.
85. Matsumoto H., Shinzaki S., Narisada M., Kawamoto S., Kuwamoto K., Moriwaki K., et al. Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer. Clinical Chemistry and Laboratory Medicine: CCLM/FESCC 2010, 48:505-512.
86. McAllister S.S., Gifford A.M., Greiner A.L., Kelleher S.P., Saelzler M.P., Ince T.A., et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008, 133:994-1005.
87. Mehta A., Norton P., Liang H., Comunale M.A., Wang M., Rodemich-Betesh L., et al. Increased levels of tetra-antennary N-linked glycan but not core fucosylation are associated with hepatocellular carcinoma tissue. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2012, 21:925-933.
88. Melle C., Kaufmann R., Hommann M., Bleul A., Driesch D., Ernst G., et al. Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip technology. International Journal of Oncology 2004, 24:885-891.
89. Mendelsohn R., Cheung P., Berger L., Partridge E., Lau K., Datti A., et al. Complex N-glycan and metabolic control in tumor cells. Cancer Research 2007, 67:9771-9780.
90. Mirza M., Shaughnessy E., Hurley J.K., Vanpatten K.A., Pestano G.A., He B., et al. Osteopontin-c is a selective marker of breast cancer. International Journal of Cancer. Journal International du Cancer 2008, 122:889-897.
91. Miyoshi E., Nishikawa A., Ihara Y., Gu J., Sugiyama T., Hayashi N., et al. N-acetylglucosaminyltransferase III and V messenger RNA levels in LEC rats during hepatocarcinogenesis. Cancer Research 1993, 53:3899-3902.
92. Miyoshi E., Noda K., Yamaguchi Y., Inoue S., Ikeda Y., Wang W., et al. The alpha1-6-fucosyltransferase gene and its biological significance. Biochimica et Biophysica Acta 1999, 1473:9-20.
93. Mondal G., Chatterjee U., Chawla Y.K., Chatterjee B.P. Alterations of glycan branching and differential expression of sialic acid on alpha fetoprotein among hepatitis patients. Glycoconjugate Journal 2011, 28:1-9.
94. Morelle W., Flahaut C., Michalski J.C., Louvet A., Mathurin P., Klein A. Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: Application to cirrhosis. Glycobiology 2006, 16:281-293.
95. Moriwaki K., Noda K., Nakagawa T., Asahi M., Yoshihara H., Taniguchi N., et al. A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation. Glycobiology 2007, 17:1311-1320.
96. Morota K., Nakagawa M., Sekiya R., Hemken P.M., Sokoll L.J., Elliott D., et al. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, alpha-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clinical Chemistry and Laboratory Medicine 2011, 49:711-718.
97. Naitoh A., Aoyagi Y., Asakura H. Highly enhanced fucosylation of serum glycoproteins in patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 1999, 14:436-445.
98. Nakagawa T., Uozumi N., Nakano M., Mizuno-Horikawa Y., Okuyama N., Taguchi T., et al. Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. The Journal of Biological Chemistry 2006, 281:29797-29806.
99. Noda K., Miyoshi E., Gu J., Gao C.X., Nakahara S., Kitada T., et al. Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. Cancer Research 2003, 63:6282-6289.
100. Noda K., Miyoshi E., Kitada T., Nakahara S., Gao C.X., Honke K., et al. The enzymatic basis for the conversion of nonfucosylated to fucosylated alpha-fetoprotein by acyclic retinoid treatment in human hepatoma cells: Activation of alpha1-6 fucosyltransferase. Tumour Biology 2002, 23:202-211.
101. Noda K., Miyoshi E., Uozumi N., Yanagidani S., Ikeda Y., Gao C., et al. Gene expression of alpha1-6 fucosyltransferase in human hepatoma tissues: A possible implication for increased fucosylation of alpha-fetoprotein. Hepatology (Baltimore, MD) 1998, 28:944-952.
102. Nuck R., Orthen B., Reutter W. Occurrence of alpha 1-2-fucosylation in membrane glycoproteins of Morris hepatoma 7777 but not in liver. Aberrant type of fucosylation in a malignant tissue. European Journal of Biochemistry 1992, 208:669-676.
103. Ohno M., Nishikawa A., Koketsu M., Taga H., Endo Y., Hada T., et al. Enzymatic basis of sugar structures of alpha-fetoprotein in hepatoma and hepatoblastoma cell lines: Correlation with activities of alpha 1-6 fucosyltransferase and N-acetylglucosaminyltransferases III and V. International Journal of Cancer 1992, 51:315-317.
104. Okuda K., Fujimoto I., Hanai A., Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Research 1987, 47:4967-4972.
105. Ozkan H., Erdal H., Tutkak H., Karaeren Z., Yakut M., Yuksel O., et al. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Digestion 2011, 83:83-88.
106. Park K.S., Cho S.Y., Kim H., Paik Y.K. Proteomic alterations of the variants of human aldehyde dehydrogenase isozymes correlate with hepatocellular carcinoma. International Journal of Cancer. Journal International du Cancer 2002, 97:261-265.
107. Park K.S., Kim H., Kim N.G., Cho S.Y., Choi K.H., Seong J.K., et al. Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma. Hepatology (Baltimore, MD) 2002, 35:1459-1466.
108. Park H.J., Kim B.G., Lee S.J., Heo S.H., Kim J.Y., Kwon T.H., et al. Proteomic profiling of endothelial cells in human lung cancer. Journal of Proteome Research 2008, 7:1138-1150.
109. Park S.Y., Yu X., Ip C., Mohler J.L., Bogner P.N., Park Y.M. Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer Research 2007, 67:9294-9303.
110. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. International Journal of Cancer 1999, 80:827-841.
111. Paterlini-Brechot P., Vona G., Brechot C. Circulating tumorous cells in patients with hepatocellular carcinoma. Clinical impact and future directions. Seminars in Cancer Biology 2000, 10:241-249.
112. Phillips R.J., Helbig K.J., Van der Hoek K.H., Seth D., Beard M.R. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner. World Journal of Gastroenterology 2012, 18:3389-3399.
113. Pompach P., Brnakova Z., Sanda M., Wu J., Edwards N., Goldman R. Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma. Molecular & Cellular Proteomics 2013, 12:1281-1293.
114. Poon R.T., Fan S.T., Ng I.O., Won J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Annals of Surgery 2000, 231:544-551.
115. Poon T.C., Johnson P.J. Proteome analysis and its impact on the discovery of serological tumor markers. Clinica Chimica Acta; International Journal of Clinical Chemistry 2001, 313:231-239.
116. Powers T.W., Neely B.A., Shao Y., Tang H., Troyer D.A., Mehta A.S., et al. MALDI imaging mass spectrometry profiling of N-glycans in formalin-fixed paraffin embedded clinical tissue blocks and tissue microarrays. PLoS One 2014, 9(9):e106255.
117. Qiao B., Wang J., Xie J., Niu Y., Ye S., Wan Q., et al. Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach. International Journal of Molecular Medicine 2012, 29:832-840.
118. Qin L.X., Tang Z.Y. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: A review of the literature. Journal of Cancer Research and Clinical Oncology 2004, 130:497-513.
119. Reiniger I.W., Wolf A., Welge-Lussen U., Mueller A.J., Kampik A., Schaller U.C. Osteopontin as a serologic marker for metastatic uveal melanoma: Results of a pilot study. American Journal of Ophthalmology 2007, 143:705-707.
120. Riener M.O. Diagnosis of tumours of the liver and the biliary tract: New tissue and serum markers. Pathologe 2011, 32(Suppl. 2):304-309.
121. Riener M.O., Stenner F., Liewen H., Soll C., Breitenstein S., Pestalozzi B.C., et al. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (Baltimore, MD) 2009, 49:1602-1609.
122. Romano P.R., Mackay A., Vong M., deSa J., Lamontagne A., Comunale M.A., et al. Development of recombinant Aleuria aurantia lectins with altered binding specificities to fucosylated glycans. Biochemical and Biophysical Research Communications 2011, 414(1):84-89.
123. Ryden I., Lundblad A., Pahlsson P. Lectin ELISA for analysis of alpha(1)-acid glycoprotein fucosylation in the acute phase response. Clinical Chemistry 1999, 45:2010-2012.
124. Saldova R., Dempsey E., Perez-Garay M., Marino K., Watson J.A., Blanco-Fernandez A., et al. 5-AZA-2'-deoxycytidine induced demethylation influences N-glycosylation of secreted glycoproteins in ovarian cancer. Epigenetics 2011, 6:1362-1372.
125. Saldova R., Fan Y., Fitzpatrick J.M., Watson R.W., Rudd P.M. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology 2011, 21:195-205.
126. Sanda M., Pompach P., Brnakova Z., Wu J., Makambi K., Goldman R. Quantitative liquid chromatography-mass spectrometry-multiple reaction monitoring (LC-MS-MRM) analysis of site-specific glycoforms of haptoglobin in liver disease. Molecular & Cellular Proteomics 2013, 12:1294-1305.
127. Scheiffele P., Paranen J., Simons K. N-glycans as apical sorting signals in epithelial cells. Nature 1995, 378:96-98.
128. Schremmer B., Manevich Y., Feinstein S.I., Fisher A.B. Peroxiredoxins in the lung with emphasis on peroxiredoxin VI. Sub-Cellular Biochemistry 2007, 44:317-344.
129. Schwegler E.E., Cazares L., Steel L.F., Adam B.L., Johnson D.A., Semmes O.J., et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology (Baltimore, MD) 2005, 41:634-642.
130. Shalhoub P., Kern S., Girard S., Beretta L. Proteomic-based approach for the identification of tumor markers associated with hepatocellular carcinoma. Disease Markers 2001, 17:217-223.
131. Shang S., Plymoth A., Ge S., Feng Z., Rosen H.R., Sangrajrang S., et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (Baltimore, MD) 2012, 55:483-490.
132. Shi Y., Chen J., Li L., Sun Z., Zen L., Xu S., et al. A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technology in Cancer Research & Treatment 2011, 10:287-294.
133. Song P., Bao H., Yu Y., Xue Y., Yun D., Zhang Y., et al. Comprehensive profiling of metastasis-related proteins in paired hepatocellular carcinoma cells with different metastasis potentials. Proteomics. Clinical Applications 2009, 3:841-852.
134. Srivastava O.P., Hindsgaul O., Shoreibah M., Pierce M. Recognition of oligosaccharide substrates by N-acetyl-glucosaminyltransferase-V. Carbohydrate Research 1988, 179:137-161.
135. Stamataglou S.C., Hughes R.C. Cell adhesion molecules in liver function and pattern formation. The FASEB Journal 1994, 8:420-427.
136. Steel L.F., Mattu T.S., Mehta A., Hebestreit H., Dwek R., Evans A.A., et al. A proteomic approach for the discovery of early detection markers of hepatocellular carcinoma. Disease Markers 2001, 17:179-189.
137. Sun C., Chen P., Chen Q., Sun L., Kang X., Qin X., et al. Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients. Acta Biochimica et Biophysica Sinica (Shanghai) 2012, 44:765-773.
138. Sun Y., Yang H., Mao Y., Xu H., Zhang J., Li G., et al. Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. Journal of Gastroenterology and Hepatology 2011, 26:1207-1212.
139. Takashima M., Kuramitsu Y., Yokoyama Y., Iizuka N., Toda T., Sakaida I., et al. Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma. Proteomics 2003, 3:2487-2493.
140. Takeda Y., Shinzaki S., Okudo K., Moriwaki K., Murata K., Miyoshi E. Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer. Cancer 2012, 118:3036-3043.
141. Tan L.Y. Correlation between GP73 protein and human liver disease. Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology 2007, 15:958-959.
142. Tan L.Y., Chen J., Wang H., Ye H.Q., Li Q., Gu J.A., et al. Correlation between serum Golph2 protein and hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology 2009, 17:288-291.
143. Tang Z.Y., Ye S.L., Liu Y.K., Qin L.X., Sun H.C., Ye Q.H., et al. A decade's studies on metastasis of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 2004, 130:187-196.
144. Taylor-Robinson S.D., Foster G.R., Arora S., Hargreaves S., Thomas H.C. Increase in primary liver cancer in the UK. Lancet 1997, 350:1142-1143.
145. Thompson S., Guthrie D., Turner G.A. Fucosylated forms of alpha-1-antitrypsin that predict unresponsiveness to chemotherapy in ovarian cancer. British Journal of Cancer 1988, 58:589-593.
146. Tian L., Wang Y., Xu D., Gui J., Jia X., Tong H., et al. Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. International Journal of Cancer. Journal International du Cancer 2011, 129:1923-1931.
147. Tigrani D.Y., Weydert J.A. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations. American Journal of Clinical Pathology 2007, 127:580-584.
148. Tuck A.B., Chambers A.F., Allan A.L. Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management. Journal of Cellular Biochemistry 2007, 102:859-868.
149. Tuma P.L., Hubbard A.L. The hepatocyte surface: Dynamic polarity. The liver: Biology and pathobiology 2001, 98-117. Lippincott Williams & Wilkins, Philadelphia. I.M. Arias (Ed.).
150. Turner G.A. Haptoglobin. A potential reporter molecule for glycosylation changes in disease. Advances in Experimental Medicine and Biology 1995, 376:231-238.
151. Wang H.Y. Laser capture microdissection in comparative proteomic analysis of hepatocellular carcinoma. Methods in Cell Biology 2007, 82:689-707.
152. Wang X., Gu J., Ihara H., Miyoshi E., Honke K., Taniguchi N. Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. The Journal of Biological Chemistry 2006, 281:2572-2577.
153. Wang C., Hua-yu Y., Yi-lei M., Jin-chun Z., Hai-feng X., Gui-yong J., et al. Value of Golgi protein 73 monoclonal antibody in diagnosis of hepatocellular carcinoma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2011, 33:39-44.
154. Wang M., Long R.E., Comunale M.A., Junaidi O., Marrero J., Di Bisceglie A.M., et al. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiology, Biomarkers & Prevention 2009, 18:1914-1921.
155. Wang W., Zhao L.J., Wang Y., Tao Q.Y., Feitelson M.A., Zhao P., et al. Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC. Cancer Biomarkers: Section A of Disease Markers 2011, 11:29-39.
156. Wei T., Liu Q., He F., Zhu W., Hu L., Guo L., et al. The role of N-acetylglucosaminyltransferases V in the malignancy of human hepatocellular carcinoma. Experimental and Molecular Pathology 2012, 93:8-17.
157. Wen C.L., Chen K.Y., Chen C.T., Chuang J.G., Yang P.C., Chow L.P. Development of an AlphaLISA assay to quantify serum core-fucosylated E-cadherin as a metastatic lung adenocarcinoma biomarker. Journal of Proteomics 2012, 75:3963-3976.
158. White K.Y., Rodemich L., Nyalwidhe J.O., Comunale M.A., Clements M.A., Lance R.S., et al. Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. Journal of Proteome Research 2009, 8:620-630.
159. Whiteaker J.R., Zhang H., Zhao L., Wang P., Kelly-Spratt K.S., Ivey R.G., et al. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. Journal of Proteome Research 2007, 6:3962-3975.
160. Xu W.F., Fei Y.M., Zhou J.K., Shen H.J., Chen X.F., Lv Q.Q., et al. Significance of serum golgi protein 73 (GP73), alpha-fetoprotein (AFP) and lectin-reactive alpha-fetoprotein (AFP-L3) expression in primary hepatic carcinoma. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2011, 25:286-288.
161. Yamamoto K., Imamura H., Matsuyama Y., Kume Y., Ikeda H., Norman G.L., et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. Journal of Gastroenterology 2010, 45:1272-1282.
162. Yamanaka N., Tanaka T., Tanaka W., Yamanaka J., Yasui C., Kuroda N., et al. Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer 1997, 79:1509-1515.
163. Yamashita K., Taketa K., Nishi S., Fukushima K., Ohkura T. Sugar chains of human cord serum alpha-fetoprotein: Characteristics of N-linked sugar chains of glycoproteins produced in human liver and hepatocellular carcinomas. Cancer Research 1993, 53:2970-2975.
164. Ye Q.H., Qin L.X., Forgues M., He P., Kim J.W., Peng A.C., et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nature Medicine 2003, 9:416-423.
165. Yokoo H., Kondo T., Fujii K., Yamada T., Todo S., Hirohashi S. Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology (Baltimore, MD) 2004, 40:609-617.
166. Yoshimura M., Nishikawa A., Ihara Y., Taniguchi S., Taniguchi N. Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:8754-8758.
167. Yue H.Y., Cao J., Cui J.F., Dai Z., Su J.J., Duan X.X., et al. The expression of peroxiredoxin II in hepatocellular carcinoma and its significance. Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology 2007, 15:366-369.
168. Zeindl-Eberhart E., Haraida S., Liebmann S., Jungblut P.R., Lamer S., Mayer D., et al. Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology (Baltimore, MD) 2004, 39:540-549.
169. Zekri A.R., Bahnassy A.A., Alam El-Din H.M., Morsy H.M., Shaarawy S., Moharram N.Z., et al. Serum levels of beta-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma. Oncology Reports 2011, 26:825-831.
170. Zhao X.Y., Li N., Ding H.G., Jiang F.F. Detection and evaluation of serum GP73, a resident Golgi glycoprotein, as a marker in diagnosis of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology] 2010, 32:943-945.
171. Zhou Y., Yin X., Ying J., Zhang B. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: A diagnostic meta-analysis. BMC Cancer 2012, 12:17.
172. Zhu J., Lin Z., Wu J., Yin H., Dai J., Feng Z., et al. Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. Journal of Proteome Research 2014, 13:2986-2997.